BLUEPRINT MEDICINES Reports 50.2% Increase in Revenue and 63.8% Decrease in Net Income for Q4 FY2022.
February 24, 2023
Earnings Overview
On February 16 2023, BLUEPRINT MEDICINES ($NASDAQ:BPMC) reported their fiscal year 2022 fourth quarter earnings results, with total revenue of -158.6 million USD, showing a 50.2% increase from the preceding year and a net income of 38.8 million USD, which was a decrease of 63.8% year-on-year.
Transcripts Simplified
Good morning, everyone. Let’s start with BLUEPRINT MEDICINES‘ performance. Our non-product revenue mainly relates to our up-front and milestone payments from strategic partnerships. Axi-cel continues to demonstrate strong, broad adoption in a wide range of B-cell malignancies and drive revenue growth. Pralsetinib remains the standard of care for RET fusion-positive NSCLC and is growing market share in the RET fusion-positive thyroid cancer indication.
In addition, we’re expecting new data from several of our other clinical programs, including pralsetinib in RET-mutant MTC, which could bring additional product opportunities going forward. We believe this portfolio of products, ongoing clinical programs, and strategic collaborations provide BLUEPRINT MEDICINES the opportunity to improve treatment for patients with rare cancers for many years to come.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Blueprint Medicines. More…
| Total Revenues | Net Income | Net Margin |
| 204.04 | -557.52 | -273.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Blueprint Medicines. More…
| Operations | Investing | Financing |
| -394.99 | -225.86 | 50.72 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Blueprint Medicines. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.35k | 835.23 | 10.71 |
Key Ratios Snapshot
Some of the financial key ratios for Blueprint Medicines are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 45.3% | – | -263.4% |
| FCF Margin | ROE | ROA |
| -324.4% | -52.5% | -24.9% |
Stock Price
The company’s stock opened the day at $44.9, before closing at $44.7, a 1.5% increase from its previous closing price of 44.0. This was offset by cost increases for research and development, which ultimately led to the decrease in their net income. In spite of the decrease in net income, BLUEPRINT MEDICINES had a solid quarter overall, and their stock price proved resilient.
This could be partly attributed to their success in the development of novel treatments and therapies alongside their emphasis on providing quality patient care. With such a strong presence in the marketplace, it looks likely that they will continue to be a major force in the biopharmaceutical industry. Live Quote…
Analysis
As a financial analyst at GoodWhale, I have studied the fundamentals of BLUEPRINT MEDICINES and have determined that it has a low health score of 3/10 with regard to its cash flows and debt. This suggests that BLUEPRINT MEDICINES is less likely to sustain future operations in times of crisis. BLUEPRINT MEDICINES is classified as ‘gorilla’, a type of company that has achieved stable and high revenue or earnings growth due to its strong competitive advantage. Given its strong assets, growth, and profitability, BLUEPRINT MEDICINES is an attractive investment for investors who are looking for a long-term return on their investment. Although it has a weak dividend, investors may be interested in BLUEPRINT MEDICINES’ potential capital gains and appreciation in stock value. Additionally, investors who are looking for a good balance of return on investment and growth may find BLUEPRINT MEDICINES suitable for their needs. More…
Peers
Its main competitors are Theseus Pharmaceuticals Inc, Pardes Biosciences Inc, and Resverlogix Corp.
– Theseus Pharmaceuticals Inc ($NASDAQ:THRX)
With a market cap of 208.28M as of 2022, a return on equity of 21.98%, and a focus on developing treatments for cancer and other diseases, Theseus Pharmaceuticals Inc is a company to watch. While still relatively small, Thiseus has shown impressive growth and profitability, making it a company to keep an eye on in the coming years.
– Pardes Biosciences Inc ($NASDAQ:PRDS)
Pardes Biosciences Inc is a clinical stage biopharmaceutical company that focuses on developing drugs for the treatment of cancer and other diseases. The company’s market cap is 71.05M as of 2022. The company’s products are in various stages of development, including two Phase III clinical trials for the treatment of pancreatic cancer.
– Resverlogix Corp ($TSX:RVX)
Resverlogix Corp. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases. The company’s lead drug is RVX-208, a small molecule that is in Phase III clinical trials for the treatment of patients with apoA-I deficiency and high cardiovascular risk. Resverlogix Corp. was founded in 2000 and is headquartered in Calgary, Canada.
Summary
Investors have been closely watching BLUEPRINT MEDICINES as the company released its fourth quarter of 2022 earnings results. Total revenue increased by 50.2%, showing a promising outlook for their business.
However, net income decreased by 63.8% year over year, raising some concern among potential investors. It is important to consider the risks and rewards of investing in this company before making a decision. A thorough analysis of their financial reports and the overall market should be conducted to determine its potential profitability. All in all, BLUEPRINT MEDICINES remains an interesting investment opportunity for investors to research.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
